Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

NASDAQ:LEGN

Legend Biotech

Last Close

56.71

30/08 20:00

Market Cap

10.54B

Beta: −0.08

Volume Today

516.25K

Avg: 810.09K

PE Ratio

−39.80

PFCF: −29.36

Analysis Not Available